"One of the obstacles a company faces in making job-share programs work is finding qualified staff to fill the void quickly and effectively," said Todd Meyers, vice president, Innovex Primary Care Sales. "Innovex's Flex Staffing Services provides customer companies with experienced sales professionals with expertise in primary and specialty areas. These representatives undergo accelerated training and development so we can place them in the field quickly and help our customers maintain consistent territory coverage in a competitive marketplace. At the same time, this Innovex service helps customer companies fulfill the career enrichment goals of their job-share programs."

According to a survey of more than 1,000 major U.S. companies conducted by a leading human resources consulting firm, job-share programs have increased from 10 percent to 28 percent in the last 10 years. Through these programs, full-time employees cut back their hours to pursue personal goals, while the company fills the remaining hours with other staff resources. Innovex created Flex Staffing Services to provide the resources to help pharmaceutical companies implement their job-share programs.

AstraZeneca Pharmaceuticals LP has called on Innovex to provide general and specialty care sales representatives and field managers for their Flexible Work Arrangement Field Sales job-share program in the United States. "At AstraZeneca, we created the Flexible Work Arrangement Field Sales job-share program to respond to the needs of our employees," said Michael Hickey, Vice President, Field Sales, AstraZeneca. "Working with Innovex, we have delivered a service that's designed to attract and retain our most important asset: our people."

About Innovex
Innovex, a unit of Quintiles, is the world's leading commercial solutions provider and offers sales and marketing services designed to accelerate the success of pharmaceutical, biotech and medical device products. Since 1996, Innovex has created more than 94 contract sales forces in the United States, with more than 12,500 representatives who have launched more than 100 established products and 37 new products. For more information, visit www.innovex.com

Quintiles Transnational helps improve healthcare worldwide by providing a broad range of professional services, information and partnering solutions to the pharmaceutical, biotechnology and healthcare industries. Headquartered near Research Triangle Park, North Carolina, Quintiles is a member of the S&P 500 and Fortune 1000. For more information visit the company's Web site at www.quintiles.com.

About AstraZeneca
AstraZeneca (NYSE:AZN) is a major international healthcare business engaged in the research, development, manufacture and marketing of ethical (prescription) pharmaceuticals and the supply of healthcare services. It is one of the top five pharmaceutical companies in the world with healthcare sales of over $16.4 billion and leading positions in sales of gastrointestinal, oncology, anesthesia (including pain management), cardiovascular, central nervous system (CNS) and respiratory products. In the United States, AstraZeneca is an $8.7 billion healthcare business with more than 10,000 employees. For more information about AstraZeneca, please visit www.astrazeneca.com.

Information in this press release contains "forward looking statements" regarding Quintiles and Innovex that involve risks and uncertainties that could cause actual results to differ materially, including without limitation, the risk that the market for our products and services will not grow as we expect, our ability to efficiently distribute backlog among therapeutic business units and match demand to resources, actual operating performance, the ability to maintain large client contracts or to enter into new contracts, changes in trends in the pharmaceutical industry, and the ability to operate successfully in new lines of business. Additional factors that could cause actual results to differ materially are discussed in Quintiles' recent filings with the Securities and Exchange Commission, including but not limited to its Annual Report on Form 10-K, its Form 8-Ks, and its other periodic reports, including Form 10-Qs.